Viking Therapeutics Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) reached $25.11 at the closing of the latest trading day, reflecting a -8.26% change compared to its last close.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.53, representing a +2.88% change from its previous close.
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.73, denoting a -2.84% move from the preceding trading day.
VKTX Advances Obesity Program With New Oral Maintenance Study
VK2735's oral maintenance study could expand Viking Therapeutics' obesity strategy by helping sustain weight loss with less frequent dosing.
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $30.51, moving 6.41% from the previous trading session.
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver
Viking Therapeutics delivered strong VK2735 maintenance trial results in obesity, showing robust induced weight loss and promising tolerability with less frequent dosing in the maintenance phase. VKTX demonstrated competitive or superior efficacy to Eli Lilly's tirzepatide and retatrutide across comparable time points, with tolerability expected to improve in phase 3 with less aggressive titration. The $500 million equity and convertible note offering temporarily pressured shares but was a necessary step to support advancing VKTX's pipeline and future spending.
Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality
Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735 in obesity. VKTX is advancing both injectable [SC] and oral VK2735, with phase 3 SC studies ongoing and phase 3 oral studies expected to initiate in Q4 2026. SC VK2735 demonstrated robust maintenance of weight loss—97% with every-other-week and 90% with monthly dosing—highlighting differentiation potential versus competitors.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44% change from its previous close.
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
